Clinical trials: Omalizumab
Cold Contact Urticaria
Cold Urticaria Treatment With Xolair
Urticaria is a very frequent skin condition characterised by transient wheal and flare type skin reactions associated with severe pruritus.
- Trial name
- CUTEX (NCT01580592)
- Testing
- Omalizumab
- Where
- 3 sites in Germany
- Volunteers
- 31 people
- Sponsor
- Charite University, Berlin, Germany
Severe Asthma
BIOmarkers in Severe AsthMa Patients on Omalizumab Treatment
Eosinophil infiltration and degranulation in airways has been implicated in the pathology of asthma. Periostin is considered to be a marker of eosinophilic inflammation and is one of the highly expressed genes in epithelial cells…
- Trial name
- BIOSAMOT (NCT03361111)
- Where
- Poland
- Volunteers
- 16 people
- Sponsor
- Medical University of Warsaw
Allergic Asthma
Effectiveness and Safety of Omalizumab in Children With Allergic Asthma.
The study was the non-interventional, retrospective study aimed to assess the effectiveness and safety of omalizumab in children with allergic asthma in China, and described patient profiles and treatment patterns of omalizumab…
- Trial name
- NCT05424523
- Testing
- Omalizumab
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations
A retrospective database analysis to evaluate the impact of omalizumab on the use of corticosteroid, emergency-department visits and hospitalizations among patients with uncontrolled asthma and using high-dose Inhaled…
- Trial name
- NCT01460862
- Sponsor
- Novartis Pharmaceuticals
Persistent Allergic Asthma
Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma
This study will evaluate the effect of omalizumab on markers of impairment in patients with inadequately controlled persistent allergic asthma on Step 4 or above therapy as defined in the 2007 National Heart, Lung, and Blood…
- Trial name
- NCT00870584
- Testing
- Omalizumab
- Where
- 50 sites in United States
- Volunteers
- 271 people
- Sponsor
- Novartis Pharmaceuticals
Sinusitis
Establishment of Precise Diagnosis and Treatment System for Refractory Chronic Rhinosinusitis
Chronic rhinosinusitis that recurs after adequate surgery and conventional medical treatment is called refractory chronic rhinosinusitis (RCRS).
- Trial name
- NCT05390255
- Testing
- Mometasone furoate nasal spray hormone, Mometasone furoate nasal spray hormone + oral hormone, Mometasone furoate nasal spray hormone + omalizumab
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Beijing Tongren Hospital
Allergic Bronchopulmonary Aspergillosis
A Prospective Study on Optimizing Treatment for ABPA
This study is being done to evaluate the efficacy of treatment using oral glucocorticoid, anti-fungal agent, anti-IgE mAb for patient with ABPA.
- Trial name
- NCT05129033
- Testing
- Prednisone tablet, itraconazole, Omalizumab
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
Hay Fever, Hypersensitivity
Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies
A series of allergy shots may reduce symptoms of seasonal ragweed allergies. This study will determine whether taking a drug called omalizumab (also known as Xolair) before getting the allergy shots is more effective than allergy…
- Conditions
- Hay Fever, Hypersensitivity, Allergy, Rhinitis
- Trial name
- NCT00078195
- Testing
- omalizumab, Ragweed rush immunotherapy (RIT), Ragweed immunotherapy (IT)
- Where
- 3 sites in United States
- Volunteers
- 168 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
ALLERGIC ASTHMA
A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy
The researcher proposes to assess levels of sputum inflammatory markers (eosinophils, eosinophil cationic protein (ECP), neutrophils IL-8) before and while on anti-IgE therapy in a pediatric population of moderate to severe…
- Trial name
- NCT00283504
- Testing
- ANTI-IGE THERAPY (XOLAIR)
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of The King's Daughters
Acute Interstitial Nephritis
Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)
The investigators goal is to evaluate the role of XOLAIR® in treatment of Acute Tubulointerstitial Nephritis (AIN) with the goal of shortening the duration and dose of prednisone for treatment of drug-induced AIN.
- Trial name
- NCT01893658
- Testing
- Omalizumab, Prednisone
- Where
- United States
- Sponsor
- Mayo Clinic
Autism Spectrum Disorder, Atopy
Xolair Interventional Study in ASD Patients With Comorbid Atopy
Following the publication of two case studies that reported behavioral benefit in ASD patients treated with omalizumab, the investigators will conduct a pilot trial to test the proof-of-concept efficacy of omalizumab in ASD…
- Trial name
- NCT04535817
- Testing
- Omalizumab Injection [Xolair]
- Where
- United States
- Sponsor
- Beth Israel Deaconess Medical Center
Chronic Urticaria
Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
The purpose of the study is to compare the efficacy, pharmacokinetics, pharmacodynamics, safety, tolerability, and immunogenicity of TEV-45779 compared to XOLAIR in patients with Urticaria (CIU)/Chronic Spontaneous Urticaria…
- Trial name
- NCT04976192
- Testing
- TEV-45779, XOLAIR® Injection
- Where
- 9 sites in United States
- Volunteers
- 608 people
- Sponsor
- Teva Pharmaceuticals USA
Allergic Rhinitis
The Effect of Omalizumab on Responses to Cat Allergen Challenge
This research is being done to study the effects of the drug omalizumab (Xolair) in people with cat allergies. The investigators will use omalizumab to study changes in the cells in the nose, skin and blood that cause allergies.
- Trial name
- NCT00604786
- Testing
- omalizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Johns Hopkins University
Chronic Spontaneous Urticaria
OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients
This trial assessed the efficacy of optimized re-treatment therapy with omalizumab (150mg or 300mg) after relapse, in participants with Chronic Spontaneous Urticaria who were clinically well-controlled following their first…
- Trial name
- OPTIMA (NCT02161562)
- Testing
- omalizumab
- Where
- 35 sites in Argentina, Brazil and 6 more
- Volunteers
- 314 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States
A retrospective database pre-post cohort study, identifying asthmatic patients, aged 6- 11, with omalizumab use over 24 months
- Trial name
- NCT05157087
- Testing
- Omalizumab
- Where
- United States
- Volunteers
- 16,246 people
- Sponsor
- Novartis Pharmaceuticals
Nasal Polyps
Omalizumab Efficacy in Patients With Refractory Nasal Polyps
in patients with chronic rhinosinusitis with nasal polyps and concomitant asthma, they have a poor therapeutic response and a higher recurrence rate, and treatment in these patients often fails.
- Trial name
- NCT05405478
- Testing
- Omalizumab, SNOT22 score
- Where
- Iran
- Volunteers
- 2 people
- Sponsor
- Shiraz University of Medical Sciences
Food Allergy
Protection From Food Induced Anaphylaxis by Reducing the Serum Level of Specific IgE (Protana).
Anaphylaxis elicited by accidental intake of the offending food constitutes a major health risk to the food allergic patient. Current advice for the food allergic patient is to avoid the offending food allergen and to carry an…
- Trial name
- NCT03964051
- Testing
- Omalizumab Injection
- Where
- Denmark
- Volunteers
- 7 people
- Sponsor
- Carsten Bindslev-Jensen
Allergic Asthma
Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years)
The primary purpose of this study is to examine whether the geometric mean of serum free IgE level at 24 weeks of the treatment period in Japanese pediatric patients (6 to 15 years of age) reaches under 25 ng/mL (target level).
- Trial name
- NCT01155700
- Testing
- omalizumab
- Where
- 17 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Food Allergy
Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients
This is a pilot randomized, double-blind, placebo controlled study which will be conducted at a single center. All participants will receive oral immunotherapy for their specific food allergies (limited to 5 of those food…
- Trial name
- MAP-X (NCT02643862)
- Testing
- Xolair
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Stanford University
Gastroenteritis
Omalizumab to Treat Eosinophilic Gastroenteritis
This study will evaluate the safety and usefulness of omalizumab (anti-IgE, Xolair) in reducing eosinophil counts and improving symptoms in patients with eosinophilic gastroenteritis (EG).
- Trial name
- NCT00084097
- Testing
- Omalizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)